Program
Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose
A development code. Also written as “Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose”.
Its studies are mostly in Herpes Zoster, led by Sinocelltech Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 11 open or running | phase 2since Jan 24, 2025 | Jan 24, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2025First study: phase 2 study in Herpes ZosterFirst studyNCT06801509 · 540 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06801509Herpes Zoster · China | 2 | Not yet recruiting | Nov 10, 2025 | 540 |
How it is read
Names in the registry
- “Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose”, 1 entry
- “Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose”, 1 entry
Codes read as this program: SCTV04C.
Conditions, from the studies’ own filings
- Herpes Zoster, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.